Kyowa Pharmaceutical Industry Co. Ltd, the Japanese subsidiary of pharmaceutical major Lupin, has entered into a strategic asset purchase agreement with Japan’s Shionogi & Co. Ltd. to acquire 21 brands for 15.4 billion yen (approximately Rs.1,000 crore). The deal will be effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorisation of the products to Kyowa, Lupin said in a filing with the stock exchanges.
The 21 brands cover therapy areas such as Central Nervous System (CNS), Oncology, Cardiovascular and Anti-infectives. Nine out of these 21 address the CNS therapy segment, while the remaining include three in the cardiovascular segment, three in gastro-intestinal, two in oncology and four in anti-infective products.
Nilesh Gupta, MD, Lupin, said: “This acquisition marks Lupin’s foray into the Japanese branded market in-line with our aspirations to build and strengthen our speciality business globally. The new branded product portfolio has a strong fit with Lupin’s Kyowa business, as it adds depth and reach to its current CNS portfolio.”